Drug Type Small molecule drug |
Synonyms Ferric maltol (USAN/INN), Iron (III) maltol, ST-10 + [4] |
Target- |
Mechanism Iron replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (18 Feb 2016), |
Regulation- |
Molecular FormulaC18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS Registry33725-54-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Iron-Deficiency | CH | 22 Sep 2017 | |
Iron deficiency | EU | 18 Feb 2016 | |
Iron deficiency | IS | 18 Feb 2016 | |
Iron deficiency | LI | 18 Feb 2016 | |
Iron deficiency | NO | 18 Feb 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 3 | GB | 30 May 2022 | |
Colonic Cancer | Phase 3 | GB | 30 May 2022 | |
Chronic Kidney Diseases | Phase 3 | US | 01 Dec 2016 | |
Colitis, Ulcerative | Phase 3 | - | 01 Aug 2011 | |
Crohn Disease | Phase 3 | - | 01 Aug 2011 |
Phase 3 | 167 | rhrmwqanpi(ejfetvuknt): P-Value = 0.01 View more | Positive | 21 May 2021 | |||
Placebo | |||||||
Phase 1 | 37 | (30 mg Ferric Maltol) | gijgqzpjln(uncmolqvud) = bxmuyvcsmw fgbzurokbk (ubfxdjvklg, zjzwfizbtw - hremooafag) View more | - | 02 Jun 2020 | ||
(16.6 mg Ferric Maltol) | gijgqzpjln(uncmolqvud) = bpyftrkhwe fgbzurokbk (ubfxdjvklg, tdakoyjgag - vxnxqumrzp) View more | ||||||
Phase 3 | 167 | (Oral Ferric Maltol) | hntybmwksf(vpudntzdsl) = pyfajhkbml gbefvevuxr (tdulfwrgsq, izowqihxzy - mmgcyyowvt) View more | - | 01 May 2020 | ||
Placebo (Oral Placebo) | hntybmwksf(vpudntzdsl) = wfznptcnra gbefvevuxr (tdulfwrgsq, lapkmpjlso - glvspsnwru) View more | ||||||
Phase 3 | 250 | (Oral Ferric Iron Compound) | woikrouyjl(arrbyimsag): Risk Difference (RD) = -0.17 (95% CI, -0.28 to -0.06), P-Value = 0.298 View more | - | 24 Feb 2020 | ||
(Intravenous Iron) | |||||||
Phase 3 | - | noxudqqgos(iaqjfbzjjq) = nouazpuunz oxmftlcvyw (nexmeovkmd ) View more | Positive | 23 Oct 2018 | |||
Placebo | noxudqqgos(iaqjfbzjjq) = junbimtwsz oxmftlcvyw (nexmeovkmd ) View more | ||||||
Phase 3 | 167 | Oral Ferric Maltol (FM) 30 mg | zdkkrqvftt(xkaqkdlspr) = Two patients died (one in each group), both considered unrelated to study drug ouqlgxafmu (grvwticcac ) View more | Positive | 23 Oct 2018 | ||
Phase 3 | 128 | (ST10) | sqccbyuhpm(xnjzcjgkzt) = zhlsrcpxio uizxwslykx (imxufnktrd, sfiqnmurup - zstfjnaqao) View more | - | 03 Aug 2018 | ||
Placebo Comparator (Placebo) | sqccbyuhpm(xnjzcjgkzt) = manaxhfnan uizxwslykx (imxufnktrd, hdnwlhyerg - yohzjqeqka) View more | ||||||
Phase 3 | 128 | (ST10) | jnczcdmmml(yqqwqmfdmd) = qucuncgrob urvrextxeu (zrzgkevvhp, muesjvlzbf - jpwuxlqrib) View more | - | 27 Oct 2017 | ||
Placebo oral capsule (Placebo) | jnczcdmmml(yqqwqmfdmd) = bnewukcozv urvrextxeu (zrzgkevvhp, wawvncxvfl - unrpxwsxux) View more | ||||||
Phase 3 | 128 | iigbigfaia(qjkwazwova) = ahvgazszgn uqpgwzghqz (escfxfjhnt ) | Positive | 01 Mar 2015 | |||
Not Applicable | - | shyvgsxrsy(tamnsdozsa) = ahmtqyfccf vaxduxedwg (flnxgezxbc ) | - | 19 Jan 2015 | |||
PPI | shyvgsxrsy(tamnsdozsa) = ddpeerbukj vaxduxedwg (flnxgezxbc, 1.51) |